|Bid||69.75 x 100|
|Ask||70.08 x 100|
|Day's Range||69.85 - 73.00|
|52 Week Range||66.62 - 110.81|
|Beta (3Y Monthly)||1.46|
|PE Ratio (TTM)||18.25|
|Earnings Date||Jan 23, 2019 - Jan 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||107.90|
Anheuser-Busch InBev (BUD), International Business Machines Corp. (IBM), Celgene Corp. (CELG) and American International Group Inc. (AIG) have declined to their three-year lows
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren’t very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show a strong ability […]
Investing.com - Health care stocks took a dive midday after medical device company Cooper posted lower-than-expected results.
Making money in stocks amid an uncertain market (see our 2019 outlook) will require careful choices. It will be difficult to top the revenue and earnings growth rates in 2019, for instance, and economic growth is expected to slow. That kind of environment requires investors to be discerning when it comes to their stock picks. Investors looking for the best stocks to buy for 2019 should start with these 19 companies. These firms, ranging from a money-center bank to a bargain-basement retailer, have solid prospects in 2019. We've also listed five stocks you should consider parting ways with. Check them out. SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond
OncoMed's clinical trial failures prevented the Redwood City company from achieving the financial promise of deals with Celgene, Bayer and GlaxoSmithKline. Now a London company is reverse merging with it to get its NASDAQ listing and Peninsula facility.
J&J (JNJ) presents positive data from late-stage studies evaluating its blood cancer drugs, Imbruvica and Darzalex, in the first-line setting at ASH.
This week, focus was on data presented at the annual conference of the American Society of Hematology from Dec 1-4. Apart from this, the regular pipeline updates were also in focus in the biotech sector.
Johnson & Johnson (JNJ) inks a global deal with Europe's argenx to jointly develop and globally commercialize the latter's prospective antibody, cusatuzumab.
Johnson & Johnson's blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed on Tuesday. The injection when used with standard of care drugs, Celgene Corp's Revlimid and dexamethasone, reduced the risk of the disease spreading or death by 44 percent at about 28 months in patients who are not eligible for stem cell transplant. At 30 months, the cancer did not spread in 71 percent of patients who were administered the Darzalex combination therapy, compared with 56 percent of patients on the standard of care treatment, the company said.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 3) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
82% overall response rate observed in heavily pre-treated patients
Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc's Yescarta were still responding to the cell therapy after at least two years of follow-up, the company said on Sunday. The question of how long patients will benefit from Yescarta and other therapies in an expensive new class known as chimeric antigen receptor T-cell therapies, or CAR-Ts, has been a key topic at the annual meeting of the American Society of Hematology (ASH) in San Diego. Both Yescarta and rival Kymriah from Novartis AG have U.S. prices for lymphoma of $373,000 for health insurers including the Medicare government program for seniors.
Pivotal phase 3 data show investigational R2 significantly extended progression-free survival compared with rituximab plus placebo
The data were presented by Nina Shah, M.D., University of California, San Francisco, as an oral presentation at the 60th Annual Meeting of the American Society of Hematology (ASH). bb21217 is an investigational anti-BCMA CAR T cell therapy that uses the bb2121 chimeric antigen receptor (CAR) molecule with a manufacturing process designed to improve CAR T cell functional persistence. “Anti-BCMA CAR T therapy with bb2121 has shown clinical responses in a substantial proportion of patients with relapsed/refractory multiple myeloma.
Large-cap pharma stocks are seeing some upward momentum and are on track to finish the year with handsome gains. As the year draws to a close, it remains to be seen if these stocks can sustain the ongoing ...
Pivotal phase 3 data demonstrated treatment with investigational luspatercept resulted in statistically significant increased red blood cell transfusion independence compared to pl